Drugs / HRS-3738
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05363800 | Jun 2022 → Dec 2026 expected | non-Hodgkin lymphoma | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-3738 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05363800 ↗ |
| Route | Oral | “HRS-3738 will be taken in oral.” NCT05363800 ↗ |